化学性质：                                                                                                             

产品描述：                                                                                                             

MLN8054 is a potent of Aurora A kinase (AAK) inhibitor consisting of a benzazepine core scaffold with a fused amino pyrimidine and an aryl carboxylic acid which represents an unprecedented kinase inhibitor framework. The inhibition of MLN8054 towards AAK is ATP-competitive, reversible and selective with an IC50 value of 4nM, which is more than 40-fold and 100-fold selective comparing to Aurora B kinase (IC50 = 175 nM) and a range of other kinases respectively. MLN8054 exerts antitumor activity against human tumor xenografts through AAK inhibition, which results in deactivation of Pt288, spindle defects, accumulation of G2/M, and apoptosis-induced cell death in tumor cells.

10mM (in 1mL DMSO)

10mg

50mg

200mg

Purity: >98.00%

1222800-79-4

N-(3-(dimethylamino)propyl)-4-(8-hydroxyquinolin-6-yl)benzamide

Canonical SMILES CN(CCCNC(C1=CC=C(C2=CC(O)=C3C(C=CC=N3)=C2)C=C1)=O)C

分子式 C21H23N3O2 349.43

溶解度 ≥ 17.45mg/mL in DMSO  储存条件 Store at -20°C

产品描述ML324 is a potent and cell-permeable JMJD2 demethylase inhibitor (IC50 = 920 nM). [1]

Jumonji-domain-containing proteins (JMJD) is the largest class of N ε -methyl lysine demethylase, an enzyme that demethylates the tri-methylated H3K9. JMJD takes part in gene transcription regulation. [1]

ML324 acted as an antiviral agent that effectively inhibited HSV and hCMV IE gene expression in HFF and MRC-5 cells, resulted in suppression of HSV plaques formation and inhibition of HSV infection spread. [1]

ML324 also blocked HSV-1 reactivation and inhibited the formation of HSV plaque in mouse ganglia explant model of latently infected mice. [1]

特别提醒：